Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | PSMD14 | O00487 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723525 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL13724027 | 0.84 | MEN1 (0.71) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL13724457 | 0.84 | MEN1 (0.71) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL13724455 | 0.84 | MEN1 (0.71) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL13724025 | 0.84 | MEN1 (0.71) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL21215893 | 0.84 | PIKFYVE (0.73) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL16756021 | 0.83 | PIKFYVE (0.72) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL16756020 | 0.83 | PIKFYVE (0.72) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL13727053 | 0.82 | KMT2A (0.76) | MAPTMEN1KMT2APSMD14L3MBTL1 | |
| SCHEMBL13824754 | 0.82 | KMT2A (0.76) | MAPTMEN1KMT2APSMD14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9028796-B2 | Materials and methods useful to induce cell death via methuosis | THE UNIVERSITY OF TOLEDO (US) | 2015-05-12 | — | — | US | claimed |
| US-20140322128-A1 | Materials and Methods Useful to Induce Cell Death via Methuosis | THE UNIVERSITY OF TOLEDO (US) | 2014-10-30 | — | — | US | claimed |
| WO-2012145069-A2 | MATERIALS AND METHODS USEFUL TO INDUCE CELL DEATH VIA METHUOSIS | THE UNIVERSITY OF TOLEDO (US) | 2012-10-26 | — | — | WO | claimed |
| CN-116789642-A | Tri-aromatic heterocyclic piperazine compound for inducing tumor cell to generate meta death and application thereof | 华东师范大学 | 2023-09-22 | — | — | CN | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| EP-3217970-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | Del Mar Pharmaceuticals (CA) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077264-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | DEL MAR PHARMACEUTICALS (CA) | 2016-05-19 | — | — | WO | disclosed |
| US-9061994-B1 | Materials and methods useful to induce vacuolization, cell death, or a combination thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-04 | — | — | US | disclosed |
| US-9028796-B2 | Materials and methods useful to induce cell death via methuosis | THE UNIVERSITY OF TOLEDO (US) | 2015-05-12 | — | — | US | disclosed |
| US-9023871-B2 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140322128-A1 | Materials and Methods Useful to Induce Cell Death via Methuosis | THE UNIVERSITY OF TOLEDO (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2012145069-A2 | MATERIALS AND METHODS USEFUL TO INDUCE CELL DEATH VIA METHUOSIS | THE UNIVERSITY OF TOLEDO (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | BECN1, BAD, BAX | MAPT 2529/4885MEN1 1465/4885KMT2A 3031/4885 |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | BECN1, BAD, BAX | MAPT 2529/4885MEN1 1465/4885KMT2A 3031/4885 |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | MGMT, DCLRE1A, DNMT1 | MAPT 4340/4885MEN1 1198/4885KMT2A 1245/4885 |
| US-20140322128-A1 | Materials and Methods Useful to Induce Cell Death via Methuosis | MCL1, BAX, BCL2 | MAPT 3329/4885MEN1 2167/4885KMT2A 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.